The Global Cord Blood Banking Services Market size is expected to reach $2.9 billion by 2028, rising at a market growth of 13.1% CAGR during the forecast period.
A large number of genetic illnesses can be treated with stem cells from cord blood, which is a major source of these cells. Chronic illnesses like cancer, blood diseases, diabetes, and immunological disorders can be treated with cord blood stem cells. Even while only a tiny amount of cord blood can be extracted from a single umbilical cord, it is the only type of stem cell that can be preserved for use in the future and contains a substantial number of stem cells.
These cells can be kept in cord blood banks for an average of 20 to 25 years and are obtained from hospitals and nursing homes for use in the future. The motivation of healthcare businesses to invest in research and the commercialization of cord blood stem cell therapies has increased as a result of the government authorities' support for cord blood stem cell research & clinical trials.
The market is currently more competitive, and businesses are working to spread the word about the advantages of cord blood banking. The Institute for Transfusion Medicine and Cord Blood Registry also teamed up to begin a multi-year project to raise awareness of cord blood cells. The expansion of the cord blood banking services market is anticipated to be aided by efforts that inform and advise expectant parents about the alternatives available for cord blood banking in relation to the various financial schemes for storage and donation.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include AMAG Pharmaceuticals, Inc., Americord Registry LLC, StemCyte, Inc., Cordlife Group Limited, cordvida, Cryo-Cell International, Inc., CryoHoldco de LatinoAmérica and Vita 34 AG
A large number of genetic illnesses can be treated with stem cells from cord blood, which is a major source of these cells. Chronic illnesses like cancer, blood diseases, diabetes, and immunological disorders can be treated with cord blood stem cells. Even while only a tiny amount of cord blood can be extracted from a single umbilical cord, it is the only type of stem cell that can be preserved for use in the future and contains a substantial number of stem cells.
These cells can be kept in cord blood banks for an average of 20 to 25 years and are obtained from hospitals and nursing homes for use in the future. The motivation of healthcare businesses to invest in research and the commercialization of cord blood stem cell therapies has increased as a result of the government authorities' support for cord blood stem cell research & clinical trials.
The market is currently more competitive, and businesses are working to spread the word about the advantages of cord blood banking. The Institute for Transfusion Medicine and Cord Blood Registry also teamed up to begin a multi-year project to raise awareness of cord blood cells. The expansion of the cord blood banking services market is anticipated to be aided by efforts that inform and advise expectant parents about the alternatives available for cord blood banking in relation to the various financial schemes for storage and donation.
COVID-19 Impact Analysis
Due to the lockdown measures in various countries and the delay in the collection and supply of cord blood used to treat diseases like immune disorders, blood diseases, diabetes, metabolic disorders, and cancer, the COVID 19 outbreak has had an impact on the expansion of the cord blood banking services industry. Numerous businesses in the market for cord blood banking services had to temporarily halt operations as a result of the COVID-19 pandemic in order to adhere to new rules put in place by the government to stop the disease's spread. The market for cord blood banking services was immediately impacted by this halt in operations in terms of revenue flow. As a result, the market experienced a gradual rebound throughout the course of the projected period.Market Growth Factors
Rising Awareness of Stem Cells' Therapeutic
More people are becoming aware of the therapeutic potential of stem cells worldwide. Health professionals are beginning to inform the parent and expecting populations about the significance and advantages of conserving cord blood stem cells, which is propelling the market's expansion.Rising Private as Well as Public Investment in Cancer Research
One of the key reasons driving the growth of the market is the increase in public-private funding and investments in cancer research to lead to improvements in cancer detection and treatment. In the upcoming years, these investments from the public as well as private sources are anticipated to present new growth possibilities for market participants.Marketing Restraining Factor
Stringent Accreditation & Licensing Standards A Challenge to Market Growth
A cord blood bank should have accreditations that are acknowledged globally. The blood bank's accreditations attest to independent evaluations of the blood bank's competence, credibility, operational effectiveness, and quality control of processing and cryopreservation procedures to guarantee the security of the umbilical cord blood stem cells that are being stored. Certifications serve as quality controls to uphold standards.Component Outlook
On the basis of component, the cord blood banking service market is divided into cord blood and cord tissue. In 2021, the cord tissue segment held the largest revenue share in the cord blood banking services market. Due to the abundance of stem cells present in cord tissue, including hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs), cord tissue is significant in cord blood banking services.Storage Services Outlook
Based on storage services, the cord blood banking services market is segmented into public and private. In 2021, the public segment acquired a substantial revenue share in the cord blood banking services market. This is because of the high fee parents were had to pay for the collecting and storage of CB units. Furthermore, compared to state banks, the customer bases of private players are growing as a result of their marketing strategies which would contribute to the market growth in this segment.Application Outlook
By application, the cord blood banking service market is fragmented into cancer disease, diabetes, blood disease, immune disorders, metabolic disorders, and others. In 2021, the diabetes segment garnered the largest revenue share in the cord blood banking services market. Diabetes affected 422 million people in 2014, up from 108 million in 1980. Compared to high-income countries, prevalence has been increasing more quickly in low-income as well as middle-income nations.
Regional Outlook
Region wise, the cord blood banking service market is analyzed across the North America, Europe, Asia Pacific and LAMEA. In 2021, the North America segment led the cord blood banking services market by generating maximum revenue share. This is because of the region's extensive private player presence and high level of public awareness. In addition, the growth of healthcare infrastructure as well as a growing number of clinical trials in the treatment of leukaemia would propel the cord blood banking market in the region.The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include AMAG Pharmaceuticals, Inc., Americord Registry LLC, StemCyte, Inc., Cordlife Group Limited, cordvida, Cryo-Cell International, Inc., CryoHoldco de LatinoAmérica and Vita 34 AG
Scope of the Study
By Component
- Cord Tissue
- Cord Blood
By Storage Services
- Private Cord Blood Banks
- Public Cord Blood Banks
By Application
- Diabetes
- Cancer Disease
- Blood Disease
- Immune Disorders
- Metabolic Disorders
- Others
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- AMAG Pharmaceuticals, Inc.
- Americord Registry LLC
- StemCyte, Inc.
- Cordlife Group Limited
- cordvida
- Cryo-Cell International, Inc.
- CryoHoldco de LatinoAmérica
- Vita 34 AG
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Global Cord Blood Banking Services Market by Component
Chapter 4. Global Cord Blood Banking Services Market by Storage Services
Chapter 5. Global Cord Blood Banking Services Market by Application
Chapter 6. Global Cord Blood Banking Services Market by Region
Chapter 7. Company Profiles
Companies Mentioned
- AMAG Pharmaceuticals, Inc.
- Americord Registry LLC
- StemCyte, Inc.
- Cordlife Group Limited
- cordvida
- Cryo-Cell International, Inc.
- CryoHoldco de LatinoAmérica
- Vita 34 AG
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 197 |
| Published | October 2022 |
| Forecast Period | 2021 - 2028 |
| Estimated Market Value ( USD | $ 1265.6 Million |
| Forecasted Market Value ( USD | $ 2936.9 Million |
| Compound Annual Growth Rate | 13.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 8 |
